Enzo Biochem Past Earnings Performance
Past criteria checks 0/6
Enzo Biochem's earnings have been declining at an average annual rate of -25%, while the Healthcare industry saw earnings growing at 5.6% annually. Revenues have been declining at an average rate of 22.3% per year.
Key information
-25.0%
Earnings growth rate
-24.0%
EPS growth rate
Healthcare Industry Growth | 8.5% |
Revenue growth rate | -22.3% |
Return on equity | -32.9% |
Net Margin | -71.1% |
Last Earnings Update | 31 Jan 2024 |
Recent past performance updates
Recent updates
Enzo Biochem: Cleaned Up And Cash-Rich But Unloved
Oct 26Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?
May 18Is Enzo Biochem (NYSE:ENZ) A Risky Investment?
Jan 03Enzo Biochem Non-GAAP EPS of -$0.18, revenue of $18.28M
Dec 12Enzo Biochem appoints Patricia Eckert as interim CFO
Oct 20Enzo Biochem Non-GAAP EPS of -$0.17, revenue of $20.28M
Oct 14Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?
Oct 04Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale
Jun 27Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?
May 03Is Enzo Biochem (NYSE:ENZ) A Risky Investment?
Dec 17Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?
Aug 24Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?
Mar 01Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?
Feb 03If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%
Jan 08Enzo Biochem nabs expanded EUA nod for testing of COVID samples
Jan 04Enzo Biochem: Betting On The Activists Now
Dec 16Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay
Dec 13Revenue & Expenses Breakdown
How Enzo Biochem makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Jan 24 | 33 | -23 | 34 | 4 |
31 Oct 23 | 32 | -25 | 34 | 4 |
31 Jul 23 | 31 | -25 | 32 | 4 |
30 Apr 23 | -23 | -34 | 16 | 3 |
31 Jan 23 | -13 | -24 | 15 | 3 |
31 Oct 22 | 13 | -23 | 23 | 2 |
31 Jul 22 | 33 | -20 | 29 | 2 |
30 Apr 22 | 112 | -7 | 54 | 4 |
31 Jan 22 | 118 | 0 | 52 | 3 |
31 Oct 21 | 116 | 5 | 51 | 3 |
31 Jul 21 | 118 | 8 | 50 | 3 |
30 Apr 21 | 112 | 1 | 48 | 4 |
31 Jan 21 | 97 | -11 | 48 | 4 |
31 Oct 20 | 84 | -21 | 48 | 4 |
31 Jul 20 | 76 | -29 | 50 | 4 |
30 Apr 20 | 77 | -31 | 50 | 4 |
31 Jan 20 | 80 | 2 | 48 | 4 |
31 Oct 19 | 80 | 1 | 48 | 4 |
31 Jul 19 | 81 | 2 | 47 | 3 |
30 Apr 19 | 83 | 2 | 49 | 3 |
31 Jan 19 | 89 | -23 | 50 | 3 |
31 Oct 18 | 95 | -16 | 51 | 3 |
31 Jul 18 | 101 | -10 | 50 | 3 |
30 Apr 18 | 106 | -4 | 49 | 3 |
31 Jan 18 | 108 | -2 | 48 | 3 |
31 Oct 17 | 108 | -2 | 47 | 3 |
31 Jul 17 | 105 | -3 | 46 | 3 |
30 Apr 17 | 106 | 34 | 49 | 3 |
31 Jan 17 | 106 | 31 | 50 | 3 |
31 Oct 16 | 104 | 39 | 52 | 3 |
31 Jul 16 | 103 | 45 | 52 | 4 |
30 Apr 16 | 102 | 18 | 53 | 4 |
31 Jan 16 | 99 | 17 | 52 | 3 |
31 Oct 15 | 98 | 6 | 51 | 3 |
31 Jul 15 | 98 | -2 | 52 | 3 |
30 Apr 15 | 97 | -14 | 52 | 3 |
31 Jan 15 | 97 | -11 | 52 | 3 |
31 Oct 14 | 97 | -11 | 52 | 3 |
31 Jul 14 | 96 | -10 | 52 | 3 |
30 Apr 14 | 94 | -10 | 50 | 3 |
31 Jan 14 | 93 | -15 | 51 | 4 |
31 Oct 13 | 92 | -17 | 52 | 4 |
31 Jul 13 | 94 | -18 | 54 | 4 |
Quality Earnings: ENZ is currently unprofitable.
Growing Profit Margin: ENZ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ENZ is unprofitable, and losses have increased over the past 5 years at a rate of 25% per year.
Accelerating Growth: Unable to compare ENZ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ENZ is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (14.9%).
Return on Equity
High ROE: ENZ has a negative Return on Equity (-32.94%), as it is currently unprofitable.